Videos

Donna’s multiple myeloma treatment changes with the help of Dr Cristina Gasparetto’s direct influence and CAR T cell therapy.

Cristina Gasparetto, MD, discusses Donna’s relationship with the drug carfilzomib for multiple myeloma therapy, as well as her second relapse.

Donna and Dr Gasparetto converse about the many first- and second-line therapies for multiple myeloma.

Cristina Gasparetto, MD, details typical multiple myeloma maintenance in comparison with Donna’s therapies, and Donna tells us about her first relapse with multiple myeloma.

We learn more about Donna’s 2 transplants, her chemotherapy, and how they impacted her quality of life.

Donna discusses her multiple myeloma diagnosis and the start of her treatment, while Dr Gasparetto educates on the importance of transplants.

Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.

Patients with cancer can advocate for themselves by researching their illnesses and treatments before an appointment, so they’re able to ask better questions, says an expert from the HealthTree Foundation for Multiple Myeloma.

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.

Adam J. Schoenfeld, MD, considers the benefits and limitations of tumor-infiltrating lymphocyte (TIL) therapy and discusses its potential impact on the treatment landscape in non–small cell lung cancer.

An expert in the management of non–small cell lung cancer defines tumor-infiltrating lymphocyte (TIL) therapy by discussing its mechanism of action and reviewing its impact in other disease states, such as myeloma.

A key opinion leader in thoracic oncology discusses factors to consider regarding emerging cell therapy options in non–small cell lung cancer, such as CAR T, TCR, and TIL therapies.

Adam J. Schoenfeld, MD, provides key insights into treatment options for patients with non–small cell lung cancer whose tumors progress after first-line therapy.

Bonnie Addario, a lung cancer survivor, explains the importance of comprehensive biomarker testing in patients with lung cancer to treat to target and coverage from insurance companies.

G. Paris Johnson is a long-term survivor of pancreatic cancer. She is now focused on advocacy and making the most of her life.

Beth shares final thoughts and advice on adapting to life with multiple myeloma, and Elie Fahed, MD, concludes with a summary of key take home messages.

Beth discusses the financial hardships she experienced due to multiple myeloma and highlights sources of financial support made available to patients.

Elie Fahed, MD, and Beth discuss the importance of communication in the management of multiple myeloma, and Mark shares advice for caregivers regarding communication.

Olympic volleyball player, April Ross, explained in an interview with CURE® that seeing her mother’s dedication to her family, despite her diagnosis, helped put things into perspective and taught her what is truly important in life.

View the entire 2021 Extraordinary Healer® Award for Oncology Nursing virtual presentation here!

As transportation to treatments is one of the many important aspects patients with cancer must consider after receiving a diagnosis, there is room for improvement in terms of accessibility and affordability, says an expert from the Patient Access Network Foundation.

Elie Fahed, MD, and Beth describe the multiple lines of social and professional support Beth received and also gave to others throughout her journey with multiple myeloma.

Beth describes her journey after treatment failure for triple-class refractory multiple myeloma, as well as improvement due to a new therapy.